Inventiva annonce la publication dans Nature Communications de résultats complémentaires de l’étude clinique de Phase II NATIVE démontrant l’amélioration de marqueurs de santé cardiométabolique chez les patients atteints de MASH/NASH traité
13 mai 2024 02h30 HE
|
INVENTIVA
Des améliorations ont été observées au niveau de la résistance à l'insuline (taux d'insuline, HOMA-IR), du métabolisme lipidique (triglycérides, HDL-cholestérol, apolipoprotéines), du contrôle de la...
Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor
13 mai 2024 02h30 HE
|
INVENTIVA
Improvements were observed for insulin resistance (insulin levels, HOMA-IR), lipid metabolism (triglycerides, HDL-cholesterol, apolipoproteins), control of glycemia (HbA1c, fasting glucose (FG)...
Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
07 mai 2024 07h00 HE
|
Madrigal Pharmaceuticals, Inc.
On March 14, 2024, received U.S. FDA approval of Rezdiffra™ (resmetirom) for the treatment of patients with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosisIn...
Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
23 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its first-quarter 2024 financial results on Tuesday, May 7,...
Clinical ink announces GlucoseReady™
23 avr. 2024 08h00 HE
|
Clinical Ink
Winston Salem, NC, April 23, 2024 (GLOBE NEWSWIRE) -- Clinical ink, a global life science technology company, today announced the launch of GlucoseReady™, a fully integrated GCP compliant digital...
Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
16 avr. 2024 16h05 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH),...
Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
09 avr. 2024 08h00 HE
|
Madrigal Pharmaceuticals, Inc.
Rezdiffra is the first and only medication approved by the FDA for the treatment of NASH (also known as “MASH”) First patients have received Rezdiffra via Madrigal’s specialty pharmacy network ...
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
26 mars 2024 06h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
21 mars 2024 07h00 HE
|
Gyre Therapeutics, Inc.
Gyre Therapeutics Expands Board of Directors with Appointment of Rodney L. Nussbaum
Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
18 mars 2024 23h58 HE
|
Madrigal Pharmaceuticals, Inc.
CONSHOHOCKEN, Pa., March 18, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic...